专利检索 ap:("UCB Biopharma SPRL" OR "Sanofi") AND inv:"Zhaoning Zhu" 第 1 页

1.

发明申请
Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity 审中-公开

公开(公告)号：US20200046723A1

公开(公告)日：2020-02-13

申请号：US16497217

申请日：2018-04-24

申请人： UCB Biopharma SPRL , SANOFI

发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu

IPC分类号： A61K31/55 , C07D487/18

摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

2.

发明授权
Fused pentacyclic imidazole derivatives 有权

公开(公告)号：US10202405B2

公开(公告)日：2019-02-12

申请号：US15513357

申请日：2015-10-02

申请人： UCB Biopharma SPRL , Sanofi

发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme

IPC分类号： C07D519/00 , C07F7/18 , C07D471/18 , C07D487/18 , C07D493/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D495/18 , C07D513/18

摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

3.

发明申请
Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity 审中-公开

公开(公告)号：US20200022988A1

公开(公告)日：2020-01-23

申请号：US16487988

申请日：2018-03-14

申请人： UCB Biopharma SPRL , Sanofi

发明人： Julien Alistair Brown , Daniel Christopher Brookings , Jag Paul Heer , James Andrew Johnson , Zhaoning Zhu

IPC分类号： A61K31/55 , C07D471/22

摘要： A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

4.

发明申请
Fused Pentacyclic Imidazole Derivatives 审中-公开

公开(公告)号：US20170305932A1

公开(公告)日：2017-10-26

申请号：US15513357

申请日：2015-10-02

申请人： UCB Biopharma SPRL , Sanofi

发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme

IPC分类号： C07D519/00 , C07D495/18 , C07D487/18 , C07D491/18 , C07F7/18 , C07D513/18

CPC分类号： C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804

摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

5.

发明授权
TNF -α modulating benzimidazoles 有权
标题翻译： TNF-α调节苯并咪唑

公开(公告)号：US09550737B2

公开(公告)日：2017-01-24

申请号：US14406848

申请日：2013-06-11

申请人： UCB Biopharma SPRL

发明人： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley

IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D491/107 , C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D405/06

CPC分类号： C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107

摘要： A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

摘要翻译： 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱眼部疾病; 和肿瘤疾病。

6.

发明授权
Substituted imidazo[1,2-a]pyrazines as TNF activity modulators 有权
标题翻译：取代的咪唑并[1,2-a]吡嗪作为TNF活性调节剂

公开(公告)号：US09475820B2

公开(公告)日：2016-10-25

申请号：US14414299

申请日：2013-07-05

申请人： UCB Biopharma SPRL

发明人： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Laura Jane Gleave , Alexander Heifetz , Victoria Elizabeth Jackson , Craig Johnstone , Deborah Leigh , James Madden , John Robert Porter , Matthew Duncan Selby , Zhaoning Zhu

IPC分类号： A61K31/4985 , C07D241/36 , C07D491/107 , C07D487/04 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08

CPC分类号： C07D491/107 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08 , C07D487/04

摘要： A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. The imidazo[1,2-a]pyrazine derivatives of the disclosure are of general formula

7.

发明授权
Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors 有权

公开(公告)号：US10464932B2

公开(公告)日：2019-11-05

申请号：US16076387

申请日：2017-02-22

申请人： UCB Biopharma SPRL

发明人： Teresa De Haro Garcia , Martin Alexander Lowe , Malcolm Maccoss , Richard David Taylor , Zhaoning Zhu

IPC分类号： C07D417/10 , C07D417/14 , A61P33/06

摘要： A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

8.

发明申请
Iminothiadiazinane Dioxide Derivatives as Plasmepsin V Inhibitors 审中-公开

公开(公告)号：US20190040053A1

公开(公告)日：2019-02-07

申请号：US16076387

申请日：2017-02-22

申请人： UCB Biopharma SPRL

发明人： Teresa De Haro Garcia , Martin Alexander Lowe , Malcolm Maccoss , Richard David Taylor , Zhaoning Zhu

IPC分类号： C07D417/10 , C07D417/14 , A61P33/06

CPC分类号： C07D417/10 , A61P33/06 , C07D417/14

摘要： A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.